MGTX - MeiraGTx says early results promising in phase 1 study of xerostomia candidate

MeiraGTx Holdings (NASDAQ:MGTX) reports that preliminary data on a phase 1 trial of AAV-haQP1 for Grade 2/3 radiation-inducted xerostomia (dry mouth) showed the candidate led to clinically meaningful improvement in symptoms and disease burden. Six of seven participants demonstrated improvement based on two patient-reported outcome measures. One participant reached 24-month assessment and the highest possible score of 7 was maintained on the McMaster Global Rate of Change PRO measure. Based on the results, MeiraGTx plans to start a phase 2 trial in 2H 2022. Seeking Alpha contributor Avisol Capital Partners, who has a neutral rating on shares, writes that the company "should be carefully watched for a derisked entry point."

For further details see:

MeiraGTx says early results promising in phase 1 study of xerostomia candidate